SUBSCRIBE
SUBSCRIBE

Metsera

NEWS
Pictured: Injection pens meant for weight-loss medications
Business
Weight-Loss Drug Startup Metsera Launches with $290M, Looks to Tap Lucrative Obesity Market
The clinical-stage biotech emerged from stealth on Thursday with several oral and injectable candidates, including a GLP-1 receptor agonist in Phase I trials, in an effort to challenge Novo Nordisk and Eli Lilly.
April 18, 2024
 · 
2 min read
 · 
Tyler Patchen
Load More
AWARDS
  • NextGen Class of 2025
JOBS
IN THE PRESS
Press Releases
Pfizer Completes Acquisition of Metsera
November 14, 2025
 · 
7 min read
Press Releases
Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera’s Board of Directors Reaffirms Support of Merger with Pfizer
November 10, 2025
 · 
9 min read
Press Releases
Novo Nordisk will not increase its proposal to acquire Metsera, Inc.
November 10, 2025
 · 
2 min read
Press Releases
Novo Nordisk submits updated proposal to acquire Metsera, Inc.
November 5, 2025
 · 
3 min read
Press Releases
Metsera Receives Amended Proposal from Novo Nordisk; Metsera Declares Novo Nordisk Amended Proposal “Superior”
November 5, 2025
 · 
13 min read
Press Releases
Metsera Receives Unsolicited Proposal from Novo Nordisk
October 31, 2025
 · 
10 min read
Press Releases
Novo Nordisk submits proposal to acquire Metsera, Inc.
October 30, 2025
 · 
2 min read
Press Releases
Metsera Reports Positive Phase 2b Results for First- and Best-in-Class Ultra-long Acting GLP-1 RA Candidate MET-097i, Enabling Rapid Transition into Phase 3
September 29, 2025
 · 
13 min read
Press Releases
Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio
September 23, 2025
 · 
13 min read
Press Releases
Metsera to Present Research Highlighting its Next-Generation Obesity Portfolio at the 61st EASD Annual Meeting
September 11, 2025
 · 
4 min read
Load More